Adragos Pharma Acquires Swiss-Based CDMO Baccinex

• Adragos Pharma, a global CDMO, has acquired Baccinex, a Swiss aseptic fill-finish manufacturer.

Adragos Pharma, a Munich-based global contract development and manufacturing organisation (CDMO), has announced the acquisition of Baccinex, a Swiss provider of aseptic fill-finish manufacturing. The acquisition enhances Adragos’ sterile manufacturing expertise, furthering its global expansion strategy. The financial terms of the transaction were not disclosed.

Located in Courroux, Switzerland, Baccinex specialises in sterile fill-finish manufacturing for liquid and lyophilized vials. Its EU-GMP and US FDA-certified facility supports clinical trial supplies and small-to-medium scale commercial production. This capability complements Adragos’ existing portfolio, creating an integrated pathway from development to commercial supply.

Commenting on the acquisition, Dr. Ursula Bausch, CEO of Baccinex, stated, “Joining Adragos Pharma marks a new chapter for Baccinex. Our shared commitment to quality, innovation, and customer-centric solutions creates an exciting synergy that will enable us to deliver even greater value to our clients worldwide.”

Dr. Andreas Raabe, CEO of Adragos Pharma, added, “The acquisition of Baccinex represents a significant milestone for Adragos. Baccinex’s proven expertise in sterile liquids and lyophilization, combined with its operational excellence, enhances our ability to provide integrated solutions from development through to commercial supply.”